Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to the FDA with an application for colon cancer in the first half of next year.
MarketIntelligenceCenter.com's patented algorithms have identified an attractive covered-call trade on Eli Lilly and Co (LLY). Look at the Nov. '14 $65.00 covered call for a net debit in the $63.00 area. This trade has a duration of 73 days. The...
INDIANAPOLIS (dpa-AFX) - The European Commission granted marketing
authorisation for Eli Lilly and Co. (LLY) and Boehringer Ingelheim's insulin
glargine product, indicated to treat diabetes in adults, adolescents and
children aged 2 years and...
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from the
AMBITION study (a randomized, double-blind, multicenter study of
first-line combination therapy with AMBrIsentan and Tadalafil
in patients with pulmonary...